ArticleiScience2024
Development of the CRISPR-Cas12a system for editing of
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The application of the CRISPR-Cas system in Pseudomonas aeruginosa infections.Molecular biology reports · 2026Review
- An efficient CRISPR-Cas12a tool for iterative genome editing, streamlined minimization, and payload engineering ofSynthetic and systems biotechnology · 2026Article
- Engineered bacteriophages for therapeutic and diagnostic applications.Disease models & mechanisms · 2025Review
- CRISPR-Cas10-Assisted Structural Modification of StaphylococcalACS synthetic biology · 2025Article
- Synthetic and Functional Engineering of Bacteriophages: Approaches for Tailored Bactericidal, Diagnostic, and Delivery Platforms.Molecules (Basel, Switzerland) · 2025Review
- Engineering Phages to Fight Multidrug-Resistant Bacteria.Chemical reviews · 2025Review
- Precision targeting of genetic variations in mixed bacterial cultures using CRISPR-Cas12a-programmed λ phages.Frontiers in microbiology · 2025Article
- Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities.Oncology reviews · 2025Review
- Engineered Phage Enables Efficient Control of Gene Expression upon Infection of the Host Cell.International journal of molecular sciences · 2024Article
- Protocol for establishing CRISPR-Cas12a for efficient genome editing of Pseudomonas aeruginosa phages.STAR protocols · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.